Meeting
2013 Genitourinary Cancers Symposium
Characteristics and outcomes of elderly patients with systemic prostate cancer (PCa) treated with peripheral androgen blockade (PAB).
Authors
Deepak Kilari
University of Rochester, Rochester, NY
Deepak Kilari , Chintan Pandya , Chunkit Fung , Deepak M. Sahasrabudhe , Ralph Anthony Brasacchio , Edward M. Messing , Lynn Sievert , Supriya Gupta Mohile
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session B: Prostate, Penile, Urethral, and Testicular Cancer, and Urothelial Carcinoma
Track
Urothelial Carcinoma,Prostate Cancer,Penile, Urethral, and Testicular Cancer
Sub Track
Prostate Cancer
Citation
J Clin Oncol 31, 2013 (suppl 6; abstr 226)
DOI
10.1200/jco.2013.31.6_suppl.226
Abstract #
226
Poster Bd #
D14
Abstract Disclosures
Similar Posters
Poster
2017 Genitourinary Cancers Symposium
A phase II study of enzalutamide (Enz) with dutasteride (Dut) or finasteride (Fin) in men ≥ 65 years with hormone-naive systemic prostate cancer (HNSPCa).
First Author: Deepak Kilari
Poster
2018 Genitourinary Cancers Symposium
Intergroup study EORTC-1532-gucg: A phase 2 randomized open-label study of oral darolutamide (ODM-201) vs. androgen deprivation therapy (ADT) with LHRH agonists or antagonist in men with hormone naive prostate cancer (PCa).
First Author: Bertrand F. Tombal
Poster
2024 ASCO Genitourinary Cancers Symposium
Neoadjuvant darolutamide plus androgen deprivation therapy for high-risk/very high-risk localized prostate cancer: A multicenter, open-labeled, single-arm phase II trial.
First Author: Junlong Zhuang
Poster
2024 ASCO Genitourinary Cancers Symposium
Phase II trial of ArtemiCoffee for men with biochemical recurrence of prostate cancer after local therapy.
First Author: Zin Myint